Clinical trials: Depression NOS
Depressive Disorder, Depression
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major Depressive Disorder (MDD)
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Orion (NCT01360866)
- Testing
- OPC-34712, Escitalopram, Fluoxetine
- Where
- 142 sites in United States, Canada and 9 more
- Volunteers
- 2,944 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Postpartum Depression
A Phase II Study of HS-10353 in Participants With Postpartum Depression
The primary purpose of this study is to determine if treatment with HS-10353 reduces depressive symptoms in participants with postpartum depression (PPD) compared to placebo as assessed by the change from baseline in the 17-item…
- Trial name
- NCT05937867
- Testing
- HS-10353 Capsules 30 mg, Oral, QN for 14 days, HS-10353 Capsules 50 mg, Oral, QN for 14 days
- Volunteers
- 96 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Depression, Major Depressive Disorder
A Trial of AXS-05 in Patients With Major Depressive Disorder
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of AXS-05 in patients with major depressive disorder (MDD).
- Trial name
- GEMINI (NCT04019704)
- Testing
- AXS-05
- Where
- 43 sites in United States
- Volunteers
- 327 people
- Sponsor
- Axsome Therapeutics, Inc.
Depression, Bipolar
Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression
The objective of this study was to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of participants with bipolar depression.
- Trial name
- NCT01396447
- Testing
- Cariprazine
- Where
- 88 sites in United States, Bulgaria and 4 more
- Volunteers
- 584 people
- Sponsor
- Forest Laboratories
Post-traumatic Stress Disorder, Depression
Evaluation of Psilocybin-Assisted Psychotherapy in Treating Severe Depression in Patients With PTSD
Post-Traumatic Stress Disorder (PTSD) is a mental disorder that may develop in people who have been exposed to a traumatic event, including actual or threatened death, serious injury, or sexual violence.
- Trial name
- SUMMIT-90 (NCT06141876)
- Testing
- APEX-002-A02
- Volunteers
- 160 people
- Sponsor
- Apex Labs Ltd.
Postpartum Depression
A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)
In this Phase 4 study, women who have been prescribed commercial ZULRESSO™ (brexanolone) by a physician as standard of care for postpartum depression (PPD) and who are planning to receive the infusion per United States…
- Trial name
- NCT04273191
- Testing
- Brexanolone
- Sponsor
- Sage Therapeutics
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without…
- Trial name
- NCT07065240
- Testing
- SPT-300
- Where
- 61 sites in United States, Bulgaria and 5 more
- Volunteers
- 360 people
- Sponsor
- Seaport Therapeutics
COVID-19
Assessment of Mental Health in Healthcare Workers Exposed to COVID-19 Patients
The recent COVID-19 outbreak has put the health care workers on the frontline to interact and provide support to the patients. Based on previous disease outbreak-associated studies, it is evident that these individuals are at a…
- Trial name
- BADS-PTSD (NCT04473118)
- Testing
- Survey
- Where
- Qatar
- Volunteers
- 25,000 people
- Sponsor
- Hamad Medical Corporation
Depression
To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fed and Fasted Conditions
To demonstrate the relative bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride capsules (Pulvules) in healthy adult males under fed and fasted conditions.
- Trial name
- NCT00913588
- Testing
- Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.), Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.), Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sandoz
Healthy Volunteer
A Screening Study To Assess The Cognition Status in Healthy Volunteers
This multi-center screening study will conduct a cognition assessment to collect reference data for comparison to patients with depression in healthy volunteers. Data will be collected for 6 weeks.
- Trial name
- NCT01926873
- Where
- 12 sites in United States, Germany and 1 more
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Major Depressive Disorder (MDD), fNIRS
Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements
This observational, longitudinal, multi-cohort study aims to evaluate functional brain activity in adults undergoing treatment for Major Depressive Disorder (MDD) at participating clinical sites.
- Trial name
- PREDICT-ACC (NCT07294924)
- Testing
- fNIRS measurement
- Where
- 2 sites in United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Kernel
Depressive Disorder, Major
A Comparison of Sertraline-reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.
This study was designed to determine if the novel combination of the SSRI, sertraline, and the NRI reboxetine will increase antidepressant efficacy without sacrificing the favorable safety profile of SSRIs.
- Trial name
- NCT00636246
- Testing
- sertraline/[S,S]-reboxetine, sertraline, [S,S]-reboxetine monotherapy
- Where
- 17 sites in Estonia, Russia
- Volunteers
- 510 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Depressive Symptoms
Combination Therapy in Patients With Depression
The purpose of the study is to compare sertraline and atomoxetine/sertraline combination therapy in patients with persistent depressive symptoms.
- Trial name
- NCT00485862
- Testing
- Atomoxetine Hydrochloride, Sertraline
- Where
- United States
- Volunteers
- 214 people
- Sponsor
- Eli Lilly and Company
Depression, Anxiety, Mental Health Issue
Clinical Outcomes of a Digital Mental Health Intervention for Moderate/Severe Depression and Anxiety
A digital mental health intervention (BetterHelp, Mountain View, CA) provides users with access to online therapy care for treatment of depression and anxiety.
- Conditions
- Depression, Anxiety, Mental Health Issue, Mental Health Wellness 2
- Trial name
- NCT07081061
- Testing
- BetterHelp
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Teladoc Health
Anxiety Depression
Probiotics Regulate Intestinal Health and Alleviate Anxiety
This study is a randomized, double-blind, placebo-controlled trial aimed primarily at investigating the effects of Weizmannia coagulans BC99 on alleviating anxiety and depression and the gut microbiota.
- Trial name
- NCT07353320
- Testing
- probiotics group
- Where
- China
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Depression
Bioequivalency Study of Protriptyline 10 mg Tablets Under Fasted Conditions
The objective of this study was to prove the bioequivalence of Protriptyline 10 mg tablets under fasted conditions
- Trial name
- NCT00754962
- Testing
- protriptyline
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Major Depressive Disorder
A Study of CX157 (TriRima) for the Treatment of Depression
The purpose of this study is to examine the efficacy of CX157 60 mg administered three times a day (180 mg daily dose) as compared to placebo in subjects with Major Depressive Disorder (MDD).
- Trial name
- CX157-200 (NCT00739908)
- Testing
- CX157 (TriRima)
- Where
- 14 sites in United States
- Volunteers
- 285 people
- Sponsor
- CeNeRx BioPharma Inc.
Depression
Electrical Vestibular Nerve Stimulation (VeNS) As a Treatment for Depression
Trial title: Effectiveness of Electrical Vestibular Nerve Stimulation in the Management of Depression The aim of this study: To better evaluate the efficacy of non-invasive electrical vestibular nerve stimulation (VeNS) as a…
- Trial name
- NCT06051864
- Testing
- Modius Mood Active Device
- Where
- India
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
Treatment Resistant Depression
A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD
This study was conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 2b study. Approximately 180 subjects with treatment resistant depression who meet all eligibility criteria will be enrolled.
- Trial name
- ENLIGHTEN (NCT05113771)
- Testing
- Liafensine
- Where
- 45 sites in United States, Canada
- Volunteers
- 197 people
- Sponsor
- Denovo Biopharma LLC
Bipolar Disorder
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451
This is a single ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD4451.
- Trial name
- AZD4451 SAD (NCT01196676)
- Testing
- AZD4451
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- AstraZeneca